Saturday, October 31, 2026

NASDAQ 100 Went Up By Over 7% In The Last 21 Sessions

NASDAQ 100 Went Up By Over 7% In The Last 21 Sessions

(VIANEWS) - NASDAQ 100 (NDX) has been up by 7.11% for the last 21 sessions. At 10:08 EST on Monday, 27 March, NASDAQ 100 (NDX) is $12,820.25.

Volume

Today's last reported volume for NASDAQ 100 is 136396439, 95.61% below its average volume of 3112199461.93.

About NASDAQ 100's yearly highs and lows, it's 22.79% up from its 52-week low and 16.02% down from its 52-week high.

Volatility

NASDAQ 100's last week, last month's, and last quarter's current intraday variation average was 0.83%, 0.34%, and 1.28%, respectively.

NASDAQ 100's highest amplitude of average volatility was 0.83% (last week), 1.16% (last month), and 1.28% (last quarter), respectively.

News about

  • According to CNBC on Saturday, 25 March, "[They're] going to be a complement to a broader S&P 500 strategy," the firm's head of research told CNBC's "ETF Edge" on Monday. "
  • According to FXStreet on Saturday, 25 March, "In the mid-North American session, the S&P 500 and the Dow Jones are climbing 0.10% and 0.06%, each at3951.28 and 32119.30, respectively. "
  • According to FXStreet on Monday, 27 March, "However, the S&P 500 Futures print mild gains around 4,010 at the latest and traces Wall Street's gains to suggest a mildly positive risk appetite."
  • According to FXStreet on Monday, 27 March, "Against this backdrop, S&P 500 Futures trace Wall Street's mild closing while the US Treasury bond yields remain pressured."

More news about NASDAQ 100 (NDX).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,514 source documents archived
Query this data → isubstrate.com